- Home
- NEWP vs PACB Comparison
NEWP vs PACB Comparison
Compare NEWP & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEWP | PACB |
|---|---|---|
| Founded | 1972 | 2000 |
| Country | Canada | United States |
| Employees | N/A | 575 |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 687.2M | 682.3M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | NEWP | PACB |
|---|---|---|
| Price | $3.37 | $2.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $4.25 | $2.08 |
| AVG Volume (30 Days) | 1.1M | ★ 8.6M |
| Earning Date | 02-06-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $154,584,000.00 |
| Revenue This Year | N/A | $4.28 |
| Revenue Next Year | N/A | $12.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.93 | $0.85 |
| 52 Week High | $4.70 | $2.73 |
Technical Indicators
Market Signals| Indicator | NEWP | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 41.05 | 48.95 |
| Support Level | $3.69 | $2.09 |
| Resistance Level | $4.32 | $2.60 |
| Average True Range (ATR) | 0.30 | 0.20 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 1.85 | 42.13 |
Price Performance
Historical ComparisonAbout NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.